Genmab Announces Abstracts to be Presented at 23rd EHA Annual Congress

Media Release

- **Seven industry sponsored abstracts regarding Genmab programs scheduled for presentation at EHA Annual Congress**
- **Two oral presentations, five poster presentations**

Copenhagen, Denmark; May 17, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that one abstract on Genmab's DuoBody-CD3xCD20 and six industry sponsored abstracts on daratumumab will be presented at the 23rd European Hematology Association (EHA) Annual Congress 2018 in Stockholm, Sweden, June 14-17. An abstract containing a pre-clinical evaluation of Genmab's proprietary DuoBody-CD3xCD20 will be presented as a poster. The daratumumab abstracts, submitted by Janssen Research & Development, LLC, include an oral presentation on ALCYONE (MMY3007), the Phase III trial of daratumumab plus bortezomib, melphalan and prednisone in newly diagnosed multiple myeloma that was the basis for the recent U.S. Food and Drug Administration approval. There will also be an oral presentation regarding the Phase II CENTAURUS (SMM2001) study of daratumumab in smoldering multiple myeloma. The abstracts have been published on the EHA website, and may be accessed via www.ehaweb.org.

"In addition to the multiple presentations of daratumumab clinical data in multiple myeloma or amyloidosis, we are very pleased that a pre-clinical evaluation of our proprietary DuoBody-CD3xCD20 product will be presented to the attendees at this year's EHA congress," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

List of Industry Sponsored Abstracts

DuoBody-CD3xCD20
CD3 Bispecific Antibody Screen Identifies CD20 as the Most Efficient Target for Elimination of B Cell Malignancies; Pre-clinical Evaluation of DuoBody-CD3xCD20 – Poster presentation, Friday, June 15, 5:30 PM – 7:00 PM CEST

Daratumumab
Daratumumab Plus Bortezomib-Melphalan-Prednisone (VMP) in Elderly (≥75 Years of age) Patients with Newly Diagnosed Multiple Myeloma Ineligible for Transplantation (ALCYONE) – Oral presentation, Friday, June 15, 12:00 PM – 12:15 PM CEST

Effects of Daratumumab on the Composition and Activation Status of Immune-Cell Populations in CENTAURUS, a Phase 2 Randomized Study of Smoldering Multiple Myeloma (SMM) Patients – Oral presentation, Sunday, June 17, 8:30 AM – 8:45 AM CEST

Subcutaneous Daratumumab (DARA SC) + Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: Safety Run-in Results of ANDROMEDA – Poster presentation, Saturday, June 16, 5:30 PM – 7:00 PM CEST

Daratumumab, Carfilzomib and Dexamethasone (D-Kd) in Lenalidomide-refractory Patients with Relapsed Multiple Myeloma (MM): Subgroup Analysis of MMY1001 – Poster presentation, Friday, June 15, 5:30 PM – 7:00 PM CEST

Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Update of the Open-label, Multicenter, Dose Escalation Phase 1b Study (PAVO) – Poster presentation, Friday, June 15, 5:30 PM – 7:00 PM CEST

Genmab Announces Abstracts to be Presented at 23rd EHA Annual Congress

Impact of Baseline Renal Function on Efficacy and Safety of Daratumumab Plus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplantation (ALCYONE) – Poster presentation, Friday, June 15, 5:30 PM – 7:00 PM CEST

About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E: rcg@genmab.com

This Media Release contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.